Merck Pre-Tax Income 2010-2024 | MRK

Merck annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
  • Merck pre-tax income for the quarter ending September 30, 2024 was $4.090B, a 27.22% decline year-over-year.
  • Merck pre-tax income for the twelve months ending September 30, 2024 was $13.720B, a 84.21% increase year-over-year.
  • Merck annual pre-tax income for 2023 was $1.889B, a 88.51% decline from 2022.
  • Merck annual pre-tax income for 2022 was $16.444B, a 18.48% increase from 2021.
  • Merck annual pre-tax income for 2021 was $13.879B, a 136.72% increase from 2020.
Merck Annual Pre-Tax Income
(Millions of US $)
2023 $1,889
2022 $16,444
2021 $13,879
2020 $5,863
2019 $7,171
2018 $8,701
2017 $6,521
2016 $4,659
2015 $5,401
2014 $17,283
2013 $5,545
2012 $8,739
2011 $7,334
2010 $1,653
2009 $15,290
Merck Quarterly Pre-Tax Income
(Millions of US $)
2024-09-30 $4,090
2024-06-30 $6,006
2024-03-31 $5,670
2023-12-31 $-2,046
2023-09-30 $5,620
2023-06-30 $-5,335
2023-03-31 $3,650
2022-12-31 $3,513
2022-09-30 $3,583
2022-06-30 $4,487
2022-03-31 $4,861
2021-12-31 $3,909
2021-09-30 $5,266
2021-06-30 $1,717
2021-03-31 $2,987
2020-12-31 $-3,422
2020-09-30 $2,706
2020-06-30 $2,741
2020-03-31 $3,838
2019-12-31 $-1,502
2019-09-30 $2,347
2019-06-30 $3,259
2019-03-31 $3,067
2018-12-31 $2,605
2018-09-30 $2,665
2018-06-30 $2,086
2018-03-31 $1,345
2017-12-31 $1,879
2017-09-30 $200
2017-06-30 $2,439
2017-03-31 $2,003
2016-12-31 $-1,356
2016-09-30 $2,887
2016-06-30 $1,504
2016-03-31 $1,624
2015-12-31 $816
2015-09-30 $2,397
2015-06-30 $807
2015-03-31 $1,381
2014-12-31 $11,811
2014-09-30 $1,490
2014-06-30 $1,891
2014-03-31 $2,091
2013-12-31 $1,225
2013-09-30 $1,525
2013-06-30 $1,245
2013-03-31 $1,550
2012-12-31 $1,334
2012-09-30 $2,218
2012-06-30 $2,680
2012-03-31 $2,507
2011-12-31 $1,581
2011-09-30 $2,352
2011-06-30 $1,672
2011-03-31 $1,729
2010-12-31 $-702
2010-09-30 $498
2010-06-30 $1,241
2010-03-31 $616
2009-12-31 $6,463
2009-09-30 $5,077
2009-06-30 $1,967
2009-03-31 $1,783
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94